Agenda: Emerging Trends & Opportunities for ctDNA MRD in Clinical Trials

8:00 am Opening Remarks & Introduction

  • Reny Analine Senior Director, BioPharma Business Development, Natera
  • Adham Jurdi Medical Director, Oncology, Natera

8:10 am Panel Discussion: Emerging Trends & Opportunities in ctDNA MRD Oncology Clinical Trials

Synopsis

• Hear academic, biopharma, and investor perspectives on how ctDNA can unlock a new clinical trial paradigm and how this might evolve in the future
• Review the key challenges and opportunities related to implementing ctDNA MRD in clinical trials
• Discover how ctDNA MRD can support early assessment of therapy efficacy, go/no-go decisions and funding applications

PANELISTS:

Darren Hodgson

Executive Director Translational Medicine, Oncology

Fernando Cruz-Guilloty

Director, Oncology Dx

Mariana Mihalusova

Vice President

Pashtoon Kasi

Director Colon Cancer Research & Precision Medicine Director for Liquid Biopsy Research

Thomas Powles

Director

astrazeneca-logo-png-astrazeneca-logo-astra-zeneca-4902
janssen
venrock
weill
BCI_blue_nofill

9:00 am Audience Q&A

9:30 am End of Event